UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

BMC cancer, 2019-06, Vol.19 (1), p.595-9, Article 595

2019

Volltextzugriff (PDF)

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Cancer Immunology, Immunotherapy, 2017-09, Vol.66 (9), p.1175-1187

2017

Volltextzugriff (PDF)

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.637-644

2022

Volltextzugriff (PDF)

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer

Nature communications, 2021-09, Vol.12 (1), p.5431-5431, Article 5431

2021

Volltextzugriff (PDF)

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis

PloS one, 2014-09, Vol.9 (9), p.e107161-e107161

2014

Volltextzugriff (PDF)

Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis

PloS one, 2016-07, Vol.11 (7), p.e0158853-e0158853

2016

Volltextzugriff (PDF)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Molecular cancer, 2021-02, Vol.20 (1), p.37-37, Article 37

2021

Volltextzugriff (PDF)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Journal for immunotherapy of cancer, 2019-11, Vol.7 (1), p.322-322, Article 322

2019

Volltextzugriff (PDF)

The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma

Nature communications, 2019-07, Vol.10 (1), p.3108-12, Article 3108

2019

Volltextzugriff (PDF)

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Cancer Immunology, Immunotherapy, 2022-05, Vol.71 (5), p.1247-1255

2022

Volltextzugriff (PDF)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Journal for immunotherapy of cancer, 2018-12, Vol.6 (1), p.155-11, Article 155

2018

Volltextzugriff (PDF)

Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review

Frontiers in immunology, 2022-07, Vol.13, p.874829-874829

2022

Volltextzugriff (PDF)

Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Journal of cancer research and clinical oncology, 2015-05, Vol.141 (5), p.909-921

2015

Volltextzugriff (PDF)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

Ai zheng, 2016-12, Vol.35 (12), p.645-646, Article 100

2016

Volltextzugriff (PDF)

Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Cancer Immunology, Immunotherapy, 2022-05, Vol.71 (5), p.1257-1257

2022

Volltextzugriff (PDF)

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Oncoimmunology, 2016-03, Vol.5 (3), p.e1094598-e1094598

2016

Volltextzugriff (PDF)

The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients

Tumor biology, 2015-05, Vol.36 (5), p.3389-3397

2015

Volltextzugriff (PDF)

Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer

Journal of cancer research and clinical oncology, 2021, Vol.147 (1), p.177-181

2021

Volltextzugriff (PDF)

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

Molecular cancer, 2019-01, Vol.18 (1), p.7-7, Article 7

2019

Volltextzugriff (PDF)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

Frontiers in immunology, 2023-01, Vol.14, p.959868-959868

2023

Volltextzugriff (PDF)

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma

Medical oncology (Northwood, London, England), 2015-03, Vol.32 (3), p.86-86, Article 86

2015

Volltextzugriff (PDF)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007327

2023

Volltextzugriff (PDF)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

Frontiers in oncology, 2021-11, Vol.11, p.754768-754768

2021

Volltextzugriff (PDF)

Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells

BMC cancer, 2023-04, Vol.23 (1), p.386-386, Article 386

2023

Volltextzugriff (PDF)

1 – 25 von 228

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(206)

Publikationsform

Sprache

Englisch
(220)
Chinesisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(172)
Life Sciences & Biomedicine
(136)
Oncology
(96)
Humans
(86)
Lung Cancer
(49)
Female
(41)
Male
(41)
Middle Aged
(35)
Aged
(31)
Adult
(29)
Chemotherapy
(28)
Lung Neoplasms - Drug Therapy
(25)
Immunotherapy
(24)
Patients
(24)
Immunology
(23)
Prognosis
(23)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(22)
Lung Neoplasms - Genetics
(22)
Mutation
(22)
Non-Small Cell Lung Cancer
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis

Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review

Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients

Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells

Suchergebnisse filtern